Opko Health Inc. - OPK STOCK NEWS

OPKO Health, Inc. (NASDAQ: OPK) announced the appointment of Roger Medel, M.D. as an independent Board member effective December 18, 2020. With this addition, the Board now consists of 11 Directors, including seven independents. Dr. Medel, co-founder of MEDNAX, Inc., brings extensive experience in healthcare services, having led MEDNAX's growth to serve 25% of sick and premature infants in the U.S. His insights are expected to enhance OPKO’s strategic execution, as stated by Chairman Dr. Phillip Frost.

OPKO Health (NASDAQ: OPK) announced participation in three virtual investor conferences. Key events include the H.C. Wainwright 6th Annual Israel Virtual Conference on November 12, 2020, featuring a fireside chat at 9:00 a.m. ET. At the Jefferies 2020 Virtual London Healthcare Conference from November 17-19, OPKO will present on November 18 at 10:15 a.m. ET, with webcasts available afterward. Lastly, the Piper Sandler 32nd Annual Virtual Healthcare Conference will take place from December 1-3, 2020, also featuring a fireside chat and one-on-one meetings.

OPKO Health, Inc. (NASDAQ: OPK) reported strong financial results for the third quarter of 2020, achieving net income of $23.7 million ($0.04 per diluted share), significantly improving from a net loss of $62.0 million in Q3 2019. Revenues soared to $428.1 million, driven by a 61% increase in COVID-19 PCR testing, totaling approximately 3.5 million tests processed. The company also initiated a Phase 2 clinical trial for RAYALDEE to treat mild-to-moderate COVID-19. Notably, RAYALDEE prescriptions rose 13% year-over-year despite pandemic-related challenges.

BioReference Laboratories, part of OPKO Health (NASDAQ:OPK), has launched a multiplex test for COVID-19 and influenza A/B, now accepting specimens across the U.S. This innovative diagnostic tool is crucial for differentiating between these infections, especially as COVID-19 cases rise. The test allows healthcare providers to obtain results from a single sample, improving efficiency and conserving resources. Samples will be collected in supervised settings, not at BioReference Patient Service Centers. The initiative supports the identification of the correct infectious agent, aiding in effective patient management.

OPKO Health, Inc. (NASDAQ: OPK) will release its financial results for Q3 2020 on October 29, 2020, after U.S. market close. A conference call will follow at 4:30 p.m. Eastern Time, featuring management discussing operational updates and financial guidance. Interested participants can pre-register for the call or access it via a live audio webcast. For those unable to attend, a replay will be available. OPKO continues to focus on leveraging its expertise in the biopharmaceutical and diagnostics sectors.

BioReference Laboratories, an OPKO Health company (NASDAQ: OPK), has launched a COVID-19 testing program for New York City schools for the 2020-2021 academic year. This initiative is part of a collaboration with NYC's Department of Health, Health + Hospitals, and the Department of Education, involving specimen collection from over 950 schools. The program aims to enhance school safety during the pandemic. BioReference is known for its comprehensive testing services and operates a network of laboratory locations across the U.S.

OPKO Health, Inc. (NASDAQ: OPK) announced participation in two virtual investor conferences. The 13th Annual Barrington Research Fall Conference will take place on September 9, 2020, with management available for one-on-one calls. The H.C. Wainwright 22nd Annual Global Investment Virtual Conference is scheduled from September 14-16, 2020, featuring a company presentation on September 15 at 10:00 a.m. ET, along with one-on-one meetings. A live webcast will be accessible on OPKO’s investor website.

BioReference Laboratories, part of OPKO Health (NASDAQ:OPK), has launched a COVID-19 testing program for New York City school principals, teachers, and staff to ensure a safer return to school. The initiative, in collaboration with the NYC Department of Health and NYC Health + Hospitals, will collect specimens for PCR testing at eight locations, operating from 8:00 a.m. to 8:00 p.m. ET until September 7. This program highlights OPKO's commitment to supporting educational safety during the pandemic.

BioReference Laboratories, an OPKO Health company (NASDAQ:OPK), launched OnkoSight Advanced^TM, a next-generation sequencing (NGS) assay for detailed DNA mutational profiling of tumors. This assay aligns with National Comprehensive Cancer Network (NCCN) and World Health Organization (WHO) guidelines, aiding insights into common cancers. It features key biomarkers like Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI) for advanced malignancies. The launch emphasizes patient-centric care through improved accuracy and faster turnaround, enhancing oncology management.